Werewolf Therapeutics Newsroom

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Simply Wall StOct 23 20:38

12 Health Care Stocks Moving In Tuesday's Intraday Session

BenzingaOct 23 00:30

Rising as much as about 390%! Bank of America predicts that these two stocks can be bought in strongly.

FX168 Financial News (North America) News: Currently, the market has entered the fourth quarter of this year, and investors are adjusting their investment portfolios for next year.

FX168Oct 21 17:45

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

GlobeNewswireOct 4 21:00

BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10

BofA Securities analyst Jason Zemansky maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate

Futu NewsSep 10 18:31 · Ratings

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Yahoo FinanceSep 3 20:00

Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $13

Leerink Partners analyst Daina Graybosch maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 31

Futu NewsAug 20 16:32 · Ratings

Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)

TipRanksAug 20 16:30 · Ratings

Express News | Werewolf Therapeutics Inc : Leerink Partners Cuts Target Price to $13 From $15

BreakingsAug 19 18:26

Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating

MT NewswiresAug 12 17:43 · Ratings

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo FinanceAug 10 22:04

Buy Rating Affirmed for Werewolf Therapeutics on Strong Candidate Progress and Promising Safety Profiles

TipRanksAug 9 19:58 · Ratings

Buy Rating Affirmed: Werewolf Therapeutics' Promising Pipeline and Financial Health

TipRanksAug 9 13:15 · Ratings

Express News | Werewolf Therapeutics: Cash & Cash Equivalents as of June 30 Enough to Fund Operational Expenses & Capex Requirements Through at Least Q1 2026

BreakingsAug 8 19:28

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Zacks Aug 8 19:20

Earnings Flash (HOWL) WEREWOLF THERAPEUTICS Reports Q2 Loss $-0.43 Per Share

MT NewswiresAug 8 19:19

Werewolf Therapeutics | 10-Q: Q2 2024 Earnings Report

SECAug 8 19:14 · Announcements

Werewolf Therapeutics 2Q Loss/Shr 43c >HOWL

Dow JonesAug 8 19:13

Werewolf Therapeutics 2Q Rev $1.14M >HOWL

Dow JonesAug 8 19:13

Express News | Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

BreakingsAug 8 19:05